HIV prevention on wheels: PrEP pills offered on mobile van for drug users
NCT ID NCT06908252
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study tests whether giving HIV prevention pills (PrEP) on a medical van is a good way to reach people who inject drugs and are at high risk for HIV. The researchers will enroll 20 adults who use drugs or are sexually active and see how many start and stay on PrEP. The goal is to see if this mobile approach helps prevent HIV in a hard-to-reach group.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Pre-Exposure Prophylaxis (PrEP) pills
- What this could lead to
- If this works, it could show that offering HIV prevention pills on a mobile medical van is an effective way to reach people who inject drugs and help prevent HIV.
- What could go wrong
- This is a very small early-stage study with only 20 participants, so results may not apply to larger groups. It focuses on feasibility, not on proving the pills prevent HIV.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
7 people
The number who actually took part.
- Started
-
Sep 2025
- Finished
-
May 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 18 years or older, active drug injection user and/or sexually active, referred from the Syringe Service Program Exclusion Criteria: * positive HIV status
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke Department of Population Health Sciences
Durham, North Carolina, 27701, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Once-Daily HIV pill with food match Twice-Daily dosing during TB treatment?
- Four weeks vs twelve weeks: can a shorter TB prevention course work?
- Can a phone app keep young people with HIV engaged in care?
- Massive Real-World database aims to map how chronic diseases interact
- How do HIV drugs behave when kidneys fail? study measures blood levels
- Can HIV-Positive mothers breastfeed without passing the virus to their babies?